ArticleJournal of neurology2024

Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.

Ludwig Kappos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.